CyGenica Limited

CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.

The most crucial issue of intracellular delivery for large molecules, especially for gene therapy, remains the cellular membrane. This biological barrier is a double-edged sword; while it prevents infectious agents from entering our body and causing disease, it also stands between the successful use of life-saving medicines and advanced therapeutic technologies.

The successful delivery of therapeutics into target cells and organelles would minimize the undesired ‘off target’ side effects and reduce the required dose.